Association between baseline hemodynamic indices, cardiotoxicity risk, and survival in women with breast cancer

The outcome of breast cancer (BrCa) women monitored by low-dose equilibrium radionuclide angiography (ERNA) remains challenging to predict. This study aims to determine whether heart rate (HR)/blood pressure (BP) ratio–based indexes, previously confirmed to predict outcomes of various diseases, also predict BrCa-therapy-related cardiotoxicity and survival. Predictors of cardiotoxicity and survival were determined among pre-therapy variables, including shock index ([SI HR/systolic BP) and age-adjusted SI (ASI), in a female BrCa cohort with normal baseline ERNA–left ventricular ejection fraction (LVEF). We included 274 women with a median age of 54.8 (interquartile range: 45.5–65.4) years, 271 treated with anthracyclines and 96 with trastuzumab. During a median follow-up of 25.9 (18.6–33.5) months, 31 women developed cardiotoxicity (LVEF: